Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.54 |
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 2/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937691 | 1.00 | HCAR3 (0.54) | HCAR3NNMTCCR6PRKAB2PRKAG1 | |
| SCHEMBL15204853 | 0.84 | HCAR3 (0.48) | HCAR3CCR6PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL15204516 | 0.84 | HCAR3 (0.48) | HCAR3CCR6PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL15204517 | 0.84 | HCAR3 (0.48) | HCAR3CCR6PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1937510 | 0.84 | HCAR3 (0.42) | HCAR3CCR6SYK | |
| SCHEMBL1937508 | 0.84 | HCAR3 (0.42) | HCAR3CCR6SYK | |
| SCHEMBL1937016 | 0.81 | IRAK4 (0.40) | HCAR3SYK | |
| SCHEMBL1937018 | 0.81 | IRAK4 (0.40) | HCAR3SYK | |
| SCHEMBL2177541 | 0.81 | CCNK (0.55) | CCR6 | |
| SCHEMBL2177547 | 0.81 | CCNK (0.55) | CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010032875-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | HCAR3 195/4885NNMT 65/4885CCR6 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.